Revenue segments as reported by the company.

Transcatheter Aortic Valve Replacement

Transcatheter Mitral and Tricuspid Therapies

Surgical Structural Heart

Critical Care

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative expenses

Research and development expenses

Intellectual property litigation expenses, net

Change in fair value of contingent consideration liabilities

Special charges

Restructuring expenses

Other operating expenses, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Edwards Lifesciences

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring systems measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Edwards Lifesciences projects robust sales growth amidst market advancements

Edwards Lifesciences showcased strong sales growth and financial performance in Q4 2022. Despite challenges like FX impacts and spotty backlog, the company remains confident in its growth outlook. Encouraging opportunities lie in TMTT and Surgical Structural Heart segments for future expansion.

Edwards Lifesciences reports robust Q1 sales, eyes global expansion

Edwards Lifesciences delivered strong sales performance in Q1, driven by key product segments and global growth.
The company faces challenges in managing expenses and navigating competitive dynamics, particularly in Japan.
Opportunities lie in continued market growth, product innovation, and efficiency enhancements across operations.
Overall, Edwards Lifesciences remains well-positioned for growth and market leadership in the cardiovascular space.

Edwards Lifesciences exceeds Q2 expectations, raises full-year guidance

Edwards Lifesciences delivered strong Q2 results, raising full year guidance and highlighting growth in key segments. While facing challenges like seasonal impacts and market recovery issues, the company remains focused on innovation and market expansion.

Edwards Lifesciences excels in Q3, poised for diversified growth

Edwards Lifesciences delivered a strong Q3 performance with growth across key segments and a positive outlook for 2023.
The company's focus on innovation, differentiated sales strategies, and patient-centric initiatives position it well for future growth.
Challenges in pricing dynamics and market competition require strategic management, while opportunities in diverse therapies and patient activation initiatives offer avenues for expansion.
Overall, Edwards Lifesciences maintains a solid financial position, supported by a robust balance sheet and a commitment to long-term growth.

Edwards Lifesciences posts strong Q4 results, eyes global growth opportunities

Edwards Lifesciences' Q4 2023 performance reflects solid financial health and strategic investments for future growth. Despite facing challenges such as rising expenses and competitive pressures, the company is well-positioned to capitalize on opportunities through innovation and market expansion.

Edwards Lifesciences reports robust Q1 sales growth and outlook

Edwards Lifesciences shows strong sales growth across key segments and raises 2024 outlook.
Investments in transcatheter platforms and positive milestones drive sustainable growth.
Challenges include managing increased expenses and ensuring center readiness for new therapies.
Opportunities in AI implementation, patient care initiatives, and diversified growth potential.

Edwards Lifesciences reports strong Q3 performance and strategic growth focus

Edwards Lifesciences delivered robust Q3 results driven by TAVR and TMTT growth, showcasing resilience and innovation.
While facing challenges in certain markets like Japan, Edwards maintains a strong competitive position and strategic focus on long-term growth.
The company's acquisitions, product advancements, and maintained guidance reflect a commitment to expansion and market leadership.
With opportunities in innovation and global expansion, Edwards is poised for continued growth and success in the medical technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Continued demand for the HemoSphere monitoring platform and Smart Recovery is likely to have contributed to the Edwards Lifesciences' (EW) Q1 growth.

What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?

IRVINE, Calif. , April 19, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2023 after the market closes on Wednesday, April 26, 2023, and will host a conference call at 5:00 p.m.

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON APRIL 26, 2023

Boston Scientific

Stryker

Stryker, Edwards Lifesciences and Boston Scientific shares outperform the broader healthcare sector as procedure volumes rebound and costs stabilize.

Medical-Device Makers Gain Amid Return to Normalcy

Abbott Labs

DexCom

Edwards Lifesciences' state-of-the-art heart valves have a big growth runway. Abbott Laboratories has received several encouraging FDA approvals recently.

3 No-Brainer Medical Device Stocks to Buy Right Now

Edwards Lifesciences Corporation saw solid underlying growth in 2022, held back by a strong dollar. The 2023 earnings guidance is a bit underwhelming, as long-term growth trends remain intact.

Edwards Lifesciences: Solid, Not Spectacular

NEW ORLEANS , March 6, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today highlighted new important data examining mortality rates and cardiac damage of early-stage aortic stenosis (AS) sufferers, along with data examining 10-year transcatheter aortic valve replacement (TAVR) re-intervention rates using real-world Medicare data.  Together these studies, presented at the American College of Cardiology ACC.23/WCC, add valuable insights to the discussion on lifetime management of patients with AS.

EDWARDS HIGHLIGHTS NEW DATA AT ACC RELATED TO LIFETIME MANAGEMENT OF AORTIC STENOSIS

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock?

Why Is Edwards Lifesciences (EW) Down 2% Since Last Earnings Report?

In Edwards Lifesciences' (EW) Smart Recovery portfolio, the adoption of FloTrac and ClearSight sensors remains strong.

Edwards Lifesciences (EW) Gains on Innovation, Margin Growth

Sonova Holding AG

SONVY vs. EW: Which Stock Is the Better Value Option?

SONVY or EW: Which Is the Better Value Stock Right Now?

Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL platform in Europe.

Edwards Lifesciences (EW) Q4 Earnings Top, Margins Increase

Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Edwards Lifesciences (EW) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Edwards Lifesciences Corp (NYSE:EW ) Q4 2022 Earnings Conference Call January 31, 2023 5:00 PM ET Company Participants Mark Wilterding - VP, IR Michael Mussallem - Chairman & CEO Scott Ullem - Corporate VP & CFO Bernard Zovighian - Corporate VP, Transcatheter Mitral & Tricuspid Therapies Daveen Chopra - Corporate VP, Surgical Heart Valve Therapies Larry Wood - Corporate VP, Transcatheter Aortic Valve Replacement Conference Call Participants Robert Marcus - JPMorgan Chase & Co. Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Matthew Miksic - Barclays Joanne Wuensch - Citibank Chris Pasquale - Nephron Cecila Furlong - Morgan Stanley Travis Steed - Bank of America Joshua Jennings - Cowen Adam Maeder - Piper Sandler Richard Newitter - Truist Securities Operator Greetings, and welcome to the Edwards Lifesciences Fourth Quarter 2022 Earnings Conference Call. [Operator Instructions]Please note, this conference is being recorded.

Edwards Lifesciences Corp (EW) Q4 2022 Earnings Call Transcript

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 4.92% and 1.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Edwards Lifesciences (EW) Q4 Earnings and Revenues Surpass Estimates

Edwards Lifesciences narrowly beat fourth-quarter forecasts, and EW stock rose in after-hours action Tuesday. The post Edwards Lifesciences Stock Jumps After Beating Fourth-Quarter Views appeared first on Investor's Business Daily.

Edwards Lifesciences Stock Jumps After Beating Fourth-Quarter Views

IRVINE, Calif. , Jan. 31, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2022.

EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS

Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Edwards Lifesciences (EW) Ahead of Earnings?

IRVINE, Calif. , Jan. 24, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2022 after the market closes on Tuesday, January 31, 2023, and will host a conference call at 5:00 p.m.

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JANUARY 31, 2023

AbbVie

Becton, Dickinson and Co.

Bruker

Danaher

Medtronic

Merck KGaA

Thermo Fisher Scientific

The Top Six Healthcare Products and Service companies are some of the most popular investments in the market. However, they offer varying financial profiles.

Ranking The Diversified Healthcare Giants

Edwards Lifesciences (EW) continues to witness strong momentum of the RESILIA portfolio globally.

Edwards Lifesciences (EW) Gains From Innovation Amid Cost Woe

Edwards Lifesciences is a high quality business by any and all measures. Edwards has an excellent financial profile, a history of organic growth as opposed to growth via M&A, and a history of returning cash to shareholders via share repurchases.

Edwards Lifesciences: Short-Term Growth Worries Have Created An Opportunity

IRVINE, Calif. , Jan. 5, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P.

EDWARDS LIFESCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Down 40%+ this year, EW is now trading at levels not seen in years. I believe the sell-off is unjust, and investors over the next few months will benefit immensely.

Edwards Lifesciences: Catalysts For 2023 And Beyond

Tesla

Accenture Plc

Arista Networks

Broadcom

Carrier Global

Charter Communications

Dow Inc

Estee Lauder

Fidelity National Information

Fortinet

Hilton Worldwide Holdings

IQVIA Hlds

Moderna

ServiceNow

Otis Worldwide

PayPal

Zoetis

In the worst year for stocks since the Great Recession, several big names are headed for their worst year on record with just one trading day left in 2022.

Tesla is not alone: 18 (and a half) other big stocks are headed for their worst year on record

Investors are optimistic about Edwards Lifesciences (EW), led by strong underlying growth across all product groups.

Here's Why You Should Retain Edwards Lifesciences (EW) Now

Advanced Micro Devices

Netflix

Amazon

Salesforce

Intel

Micron Technology

It appears to us at Smead Capital Management that investors are behaving in a way that will damage their capital and cause them to suffer stock market failure. In 2022, as the favorite tech stocks of the last ten years got trounced, individual investors poured $100 billion into mutual funds and ETFs dominated by ownership of the very stocks which have created the most damage to their results.

News for Edwards Lifesciences Stock (EW)